Neurotropic growth factors and glycosaminoglycan based matrices to induce dopaminergic tissue formation
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
Current cell replacement therapies in Parkinson's disease (PD) are limited by low survival of transplanted cell and lacking regeneration of neuronal circuitries. Therefore, bioartificial cell carriers and growth/differentiation factors are applied to improve the integration of transplants and maximize newly generated and/or residual dopaminergic function. In this work, biohybrid poly(ethylene glycol) (starPEG)-heparin hydrogels releasing fibroblast growth factor 2 (FGF-2) and glial-derived neurotrophic factor (GDNF) were used to trigger dopaminergic tissue formation by primary murine midbrain cells in vitro. Matrix-delivered FGF-2 enhanced cell viability while release of GDNF had a pro-neuronal/dopaminergic effect. Combined delivery of both factors from the glycosaminoglycan-based matrices resulted in a tremendous improvement in survival and maturation capacity of dopaminergic neurons as obvious from tyrosine hydroxylase expression and neurite outgrowth. The reported data demonstrate that glycosaminoglycan-based hydrogels can facilitate the administration of neurotrophic factors and are therefore instrumental in potential future treatments of PD.
Details
Original language | English |
---|---|
Pages (from-to) | 205-213 |
Number of pages | 9 |
Journal | Biomaterials |
Volume | 67 |
Publication status | Published - 1 Oct 2015 |
Peer-reviewed | Yes |
External IDs
PubMed | 26222283 |
---|---|
ORCID | /0000-0003-0189-3448/work/161890454 |
Keywords
ASJC Scopus subject areas
Keywords
- Cell replacement, Glycosaminoglycan, Hydrogel, Neural stem cells, Neurotrophic growth factor